Three subcutaneous injections of 100 micrograms, three weeks apart, doubled how long ten cat-allergic owners could pet their own cats before symptoms reached 5 out of 10: 16.9 minutes at baseline, 27.7 minutes by week 24, p = 0.02. Those numbers come from the only published field trial of HypoCat, a vaccine given to the cat so that allergic people in the same house react less. They also come from nine analysed volunteers, with no control group, for a product that is licensed nowhere and sold nowhere.

What is actually in the syringe

Fel d 1 is a secretoglobin made in the cat's salivary, sebaceous, lacrimal and anal glands and spread across the coat during grooming. It is the allergen that matters: 94% of cat-allergic patients carry Fel d 1-specific IgE, out of ten recognised feline allergens. What the protein does inside the cat is still unknown, which becomes relevant below. Flea and food allergy look similar and are the first things to rule out before blaming dander.

HypoCat is not a conventional vaccine. It pairs recombinant Fel d 1 with a virus-like particle grown from cucumber mosaic virus coat protein — no viral genes, so it cannot replicate — plus a tetanus-derived T-cell epitope. That repetitive particle surface is what lets the cat break tolerance to its own protein and make anti-Fel d 1 IgG, which binds allergen in saliva and tears before it reaches a human nose.

The cat-side safety record is short but clean

Across the published work, 70 cats have received the vaccine; the 2019 pooled immunogenicity report covers 54 of them. No short-term or two-year adverse effects were reported, and every vaccinated cat mounted a detectable antibody response. In the field trial, reactions were mild, cleared within 72 hours, and were less frequent after the second and third dose. Body weight, temperature and coat condition did not change, and owners reported no behavioural difference.

What changed in the ten households

Ten adults aged 21–51, living with 13 cats aged 4–13 across six breeds, were enrolled in Zurich. One was excluded from analysis for chronic urticaria, leaving nine. The cats were injected in weeks 4, 7 and 10, with a booster at week 56.

MeasureBaselineWeek 24After booster
Petting time to symptom score 516.9 min27.7 min (p=0.02)2.3× baseline
Organ-specific symptom score11.76.4–9.1 (p=0.03)6.0 at week 62
General weekly symptom score7.24.4 (p=0.023)Below baseline
Anti-Fel d 1 IgG in catsLowRising from week 10~300-fold after 2 doses

Eight of nine owners improved on both symptom measures, three hit the 45-minute ceiling of the test, and individual gains reached six-fold. Titres tracked the owners: when IgG sagged between week 24 and the booster, petting time sagged too, then recovered after the booster.

What those numbers cannot tell you

Nine people, no placebo, symptoms scored at home by the people who wanted the result. Nobody sampled Fel d 1 in the air or on the furniture, so we cannot say whether household allergen load fell or the owners tolerated the same load better. Tear allergenicity dropped in laboratory assays; airborne allergen was never measured. A 2026 review of allergen-reducing strategies states plainly that no randomised trial has shown clinically meaningful improvement in owners under real-world conditions, and that responses vary between cats — up to roughly 50% reduction in active Fel d 1, with some cats barely moving. If yours is a low responder, the schedule buys nothing.

Why the cat and not the patient

Human cat allergy treatment is mediocre. Allergen immunotherapy means 30–80 injections over three to five years, a low success rate and a real risk of systemic reactions; a peptide vaccine for cat allergy failed phase III. A monoclonal antibody against Fel d 1 works but needs monthly dosing, and the 2019 paper modelled biologics at $5,000–50,000 a year against $200–1,000 for a vaccine. That is arithmetic, not a price list. Vaccinating the cat also treats the source: one immunised cat lowers exposure for every visitor, not only the person holding the prescription.

The welfare question nobody has answered

Fel d 1 has been in the cat family for about 11 million years and varies widely between felid species — evidence that it may not be essential, not proof that neutralising it for fifteen years is harmless. No study has looked at what chronic anti-self IgG does to a cat's skin, tear film or airways. Then there is the needle: feline injection-site sarcoma runs at 8.8 cases per 100,000 vaccinations — eight studies, 14,059,036 vaccinations, 411 cases — about 1 in 10,000, with very low certainty. A small number and a serious tumour, and every new injectable adds to the denominator.

Where it stands in 2026

HypoPet AG became Saiba Animal Health, and Boehringer Ingelheim bought the company on 3 September 2024. No regulator has approved a cat allergy vaccine, none is on sale, and no launch timeline has been published. A licence would need a randomised field trial with objective endpoints, environmental allergen sampling, multi-year safety data in old and sick cats, and manufacturing at scale. Until that exists, "the cat allergy vaccine" is a promising platform with 54 cats and 10 owners behind it.

What actually works tonight

The alternatives are not equivalent, and the gaps are measurable. Medical management of cat allergy starts with an allergist, not with a breed.

StrategyBest published effectPractical limit
HEPA H13 filtrationAirborne Fel d 1 36.3 → 4.7 ng/m³; early asthmatic response 29.2% vs 87.5%No significant effect on nose and eye symptoms
Bathing the catImmediate fall in coat allergenGone within a week; back in 1–2 days
Anti-Fel d 1 IgY foodHair Fel d 1 −47% mean; 86% of cats ≥30%; half ≥50%106 cats, 12 weeks, uncontrolled
Vaccinating the catPetting time +64% in 9 ownersNot licensed, not available

The IgY diet is the only source-side product you can buy today: about $54.98 for 5.7 kg in the US, £39.49 for 2.8 kg in the UK, and ¥214 for 1.59 kg in China at November 2026 retail.

Who should wait for it, and who should not

If it reaches market, HypoCat would suit a household with one or two cats, an owner with rhinitis, itchy eyes or mild asthma, and a cat that responds to vaccination. It would not replace asthma control, would not make a cat allergen-free, and should not be trialled at home by anyone whose last exposure needed prednisolone. If rehoming is on the table, the honest option now is a household allergy plan reviewed by both a physician and a vet.

This article is for information only and does not replace veterinary or medical advice. Allergy treatment decisions belong to your physician; vaccination decisions belong to your veterinarian.

Frequently asked

Can I get my cat vaccinated against cat allergy now?

No. HypoCat has completed early-stage and field studies but no regulator has licensed it, and it is not sold anywhere as of November 2026. The developer, formerly HypoPet and now Saiba Animal Health, was acquired by Boehringer Ingelheim in September 2024 and has not published a launch date.

How much did the vaccine reduce allergens in the trial?

In the published studies, vaccinated cats made anti-Fel d 1 IgG and their tear samples became less allergenic, with reported reductions in active Fel d 1 of up to about 50% — and clear variation between cats. Airborne household allergen was not measured, so no figure exists for what a person actually breathes in.

Is a vaccinated cat still a risk for someone with asthma?

Yes. Nine of ten owners in the field trial improved, but that was an uncontrolled study and none of them were assessed for severe asthma. A cat that has been vaccinated still produces Fel d 1, just less of it, so anyone with poorly controlled asthma should treat the cat as an exposure risk until an allergist says otherwise.

Related guides